FDA Panel Reviews MDMA Therapy for PTSD
TL;DR Summary
The FDA’s Psychopharmacologic Drugs Advisory Committee is reviewing Lykos Therapeutics’ New Drug Application for MDMA-assisted therapy for PTSD. The meeting includes presentations from both the FDA and Lykos, public comments, and a vote on two questions that could influence the FDA's decision on August 11th. Key discussions involve the role of psychotherapy, trial misconduct, patient recruitment, and safety concerns. The meeting is being live-streamed on YouTube, with periodic updates provided by Psychedelic Alpha's Founder & Editor, Josh Hardman.
- Live Coverage: FDA Advisory Committee Reviews MDMA-Assisted Therapy for PTSD Psychedelic Alpha
- Up First briefing: MDMA for PTSD treatment; Biden's border policy NPR
- FDA advisers consider MDMA therapy to treat PTSD CNN
- Psychedelics Are Challenging the Scientific Gold Standard The Atlantic
- Controversy Grows as FDA Panel Prepares to Review MDMA Drug Medscape
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
12 min
vs 13 min read
Condensed
97%
2,452 → 78 words
Want the full story? Read the original article
Read on Psychedelic Alpha